These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9391700)

  • 1. Methods for preventing reactions secondary to Cremophor EL.
    Michaud LB
    Ann Pharmacother; 1997 Nov; 31(11):1402-4. PubMed ID: 9391700
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanism of anaphylactoid reactions: improper preparation of high-dose intravenous cyclosporine leads to bolus infusion of Cremophor EL and cyclosporine.
    Liau-Chu M; Theis JG; Koren G
    Ann Pharmacother; 1997 Nov; 31(11):1287-91. PubMed ID: 9391679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL.
    Theis JG; Liau-Chu M; Chan HS; Doyle J; Greenberg ML; Koren G
    J Clin Oncol; 1995 Oct; 13(10):2508-16. PubMed ID: 7595701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Well-tolerated oral cyclosporine in a case of hypersensitivity to parenteral cyclosporine in postallogeneic bone marrow transplantation.
    Moeinian M; Sotoude H; Mohebbi Z; Asadollahi-Amin A; Mozafari R
    Indian J Pharmacol; 2018; 50(2):94-96. PubMed ID: 30100659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholestasis in the rat by means of intravenous administration of cyclosporine vehicle, Cremophor EL.
    Roman ID; Monte MJ; Esteller A; Jimenez R
    Transplantation; 1989 Oct; 48(4):554-8. PubMed ID: 2799907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study.
    Szebeni J; Muggia FM; Alving CR
    J Natl Cancer Inst; 1998 Feb; 90(4):300-6. PubMed ID: 9486816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of intratumoral injection on the biodistribution and therapeutic potential of novel chemophor EL-modified single-walled nanotube loading doxorubicin.
    Liu H; Xu H; Wang Y; He Z; Li S
    Drug Dev Ind Pharm; 2012 Sep; 38(9):1031-8. PubMed ID: 22794192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology and toxicology of Cremophor EL diluent.
    Dorr RT
    Ann Pharmacother; 1994 May; 28(5 Suppl):S11-4. PubMed ID: 7915152
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of biosafety and intracellular uptake of Cremophor EL free paclitaxel elastic liposomal formulation.
    Utreja P; Jain S; Tiwary AK
    Drug Deliv; 2012 Jan; 19(1):11-20. PubMed ID: 22074176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anaphylactoid reactions associated with parenteral cyclosporine use: possible role of Cremophor EL.
    Howrie DL; Ptachcinski RJ; Griffith BP; Hardesty RJ; Rosenthal JT; Burckart GJ; Venkataramanan R
    Drug Intell Clin Pharm; 1985 Jun; 19(6):425-7. PubMed ID: 4006735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidative capacities of cardiac and skeletal muscles of heart transplant recipients: mitochondrial effects of cyclosporin-A and its vehicle Cremophor-EL.
    N' Guessan BB; Sanchez H; Zoll J; Ribera F; Dufour S; Lampert E; Kindo M; Geny B; Ventura-Clapier R; Mettauer B
    Fundam Clin Pharmacol; 2014 Apr; 28(2):151-60. PubMed ID: 23046032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporine-induced anaphylaxis.
    Kuiper RA; Malingré MM; Beijnen JH; Schellens JH
    Ann Pharmacother; 2000; 34(7-8):858-61. PubMed ID: 10928395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation.
    Zhang JA; Anyarambhatla G; Ma L; Ugwu S; Xuan T; Sardone T; Ahmad I
    Eur J Pharm Biopharm; 2005 Jan; 59(1):177-87. PubMed ID: 15567316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of oxidative stress by Taxol® vehicle Cremophor-EL triggers production of interleukin-8 by peripheral blood mononuclear cells through the mechanism not requiring de novo synthesis of mRNA.
    Ilinskaya AN; Clogston JD; McNeil SE; Dobrovolskaia MA
    Nanomedicine; 2015 Nov; 11(8):1925-38. PubMed ID: 26282378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micelles of methoxy poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization and controlled delivery of cyclosporine A.
    Aliabadi HM; Mahmud A; Sharifabadi AD; Lavasanifar A
    J Control Release; 2005 May; 104(2):301-11. PubMed ID: 15907581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct vasoconstrictor effects of sandimmune (cyclosporine A) are mediated by its vehicle cremophor EL: inhibition by the thromboxane A2/prostaglandin endoperoxide receptor antagonist ifetroban.
    Lodge NJ
    J Pharmacol Exp Ther; 1994 Nov; 271(2):730-4. PubMed ID: 7965789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic sensitivity of paclitaxel to its delivery vehicles drives distinct clinical outcomes of paclitaxel formulations.
    Li Y; Chen N; Palmisano M; Zhou S
    Mol Pharm; 2015 Apr; 12(4):1308-17. PubMed ID: 25714793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case report--suspected anaphylactic reaction to Cremophor El.
    Strachan EB
    SAAD Dig; 1981 Jan; 4(9):209. PubMed ID: 6940248
    [No Abstract]   [Full Text] [Related]  

  • 19. Propofol pharmacokinetics and pharmacodynamics assessed from a cremophor EL formulation.
    Dutta S; Matsumoto Y; Ebling WF
    J Pharm Sci; 1997 Aug; 86(8):967-9. PubMed ID: 9269876
    [No Abstract]   [Full Text] [Related]  

  • 20. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
    Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
    Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.